GNRH1 and prostate neoplasm: Lin et al. demonstrated a 10% increase in predicted 5-year CVD risk among men with type 2 DM and PC—independent of GnRH agonist use—compared with diabetic men without PC, while Griffiths et al. reported a higher, though nonsignificant, risk of acute myocardial infarction in those with both conditions relative to DM alone suggesting an additive effect of prostate tumor and PC population [47,54].